SusannaV.UlahannanMD

PubMed

• 1 citations
  A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
  Lorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, Katharina Pomej, Marta Bofill Roig, Elias Laurin Meyer, Jaekyung Che, Naoshi Nishid...> ;JHEP Reports. 2024 Feb 1
• 1 citations
  Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
  Desai, J., Alonso, G., Kim, S., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., Guren, T., Massarelli, E., Miller, W., P...> ;Nature Medicine. 2024 Jan 1
• 4 citations
  Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
  Celsa, C., Cabibbo, G., Fulgenzi, C., Scheiner, B., D'Alessio, A., Manfredi, G., Nishida, N., Ang, C., Marron, T., Saeed, A., Wietharn, B., Pinter, M., Cheon, J., Huan...> ;Journal of Hepatology. 2024 Mar 1
• 7 citations
  The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
  Jason J Luke, Manish R Patel, George R Blumenschein, Erika Hamilton, Bartosz Chmielowski, Susanna V Ulahannan, Roisin M Connolly, Cesar A Santa-Maria, Jie Wang, Shakee...> ;Nature Medicine. 2023 Nov 1
• First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.
  Erika P Hamilton, Judy S Wang, Amit M Oza, Manish R Patel, Susanna V Ulahannan, Todd Bauer, Janet L Karlix, Jorge Zeron-Medina, Giulia Fabbri, Paola Marco-Casanova, Ga...> ;Molecular Cancer Therapeutics. 2023 Oct 2
• 2 citations
  Cannabis use among adults undergoing cancer treatment.
  Desiree R Azizoddin, Amy M Cohn, Susanna V Ulahannan, Christina E Henson, Adam C Alexander, Kathleen N Moore, Laura L Holman, Laili Kharazi Boozary, Munjireen S Sifat,...> ;Cancer. 2023 Nov 1
• 2 citations
  Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
  Shubham Pant, Erika Hamilton, Susanna V Ulahannan, James F Strauss, Fadi S Braiteh, Mo Huang, Danny Chih Hsun Liaw> ;Cancer. 2023 Jun 15
• 19 citations
  Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Ag...
  Alison M Schram, Nicoletta Colombo, Edward Arrowsmith, Vivek Narayan, Kan Yonemori, Giovanni Scambia, Amelia Zelnak, Todd M Bauer, Ning Jin, Susanna V Ulahannan, Marco...> ;JAMA Oncology. 2023 Jan 1
• 17 citations
  Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
  Emerson A Lim, Johanna C Bendell, Gerald S Falchook, Todd M Bauer, Charles G Drake, Jennifer H Choe, Daniel J George, Janet L Karlix, Susanna Ulahannan, Kris F Sachsen...> ;Clinical Cancer Research. 2022 Nov 14
• 18 citations
  Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
  D V T Catenacci, Y-K Kang, H H Yoon, B Y Shim, S T Kim, D-Y Oh, A I Spira, S V Ulahannan, E J Avery, P M Boland, J Chao, H C Chung, F Gardner, S J Klempner, K-W Lee, S...> ;ESMO Open. 2022 Oct 1
• 3 citations
  Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19.
  Ram Babu Undi, Jason L Larabee, Adrian Filiberti, Susanna Ulahannan, Sheeja Aravindan, Edana Stroberg, Lisa M Barton, Eric J Duval, Sanjay Mukhopadhyay, James C Hentho...> ;Journal of Virology. 2022 Sep 14
• 24 citations
  A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
  Niharika B. Mettu, Susanna Varkey Ulahannan, Johanna C. Bendell, Ignacio Garrido-Laguna, John H. Strickler, Kathleen N. Moore, Robert J. Stagg, Ann M. Kapoun, Leonardo...> ;Clinical Cancer Research. 2021 Nov 29
• 10 citations
  A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
  Kathleen N. Moore, David S. Hong, Manish R. Patel, Shubham Pant, Susanna Varkey Ulahannan, Suzanne F. Jones, Funda Meric-Bernstam, Judy S. Wang, Raid Aljumaily, Erika ...> ;Targeted Oncology. 2021 Sep 1
• 7 citations
  Reversible HER2 antibody-drug conjugate-induced ocular toxicity.
  Anushree Sharma, Kamran M Riaz, Mohsain Gill, Amita Patnaik, Susanna Varkey Ulahannan, Judy S. Wang, Dan S. Gombos, Qiuqing Ang, Dragan Cicic, Gregory Bergonio, Cong Z...> ;Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie. 2021 Mar 13
• 18 citations
  Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
  David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna Varkey Ulahannan, Suzanne F. Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding...> ;Clinical Cancer Research. 2021 Jan 25
• 61 citations
  Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma
  Austin G. Duffy, Chi Ma, Susanna Varkey Ulahannan, Osama E. Rahma, Oxana V. Makarova-Rusher, Liang Cao, Yunkai Yu, David E. Kleiner, Jane B. Trepel, Min-Jung Lee, Yusu...> ;Clinical Cancer Research. 2017 Aug 15
• 552 citations
  Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
  Austin G. Duffy, Susanna Varkey Ulahannan, Oxana Makorova-Rusher, Osama E. Rahma, Heiner Wedemeyer, Drew Pratt, Jeremy L. Davis, Michael S. Hughes, Theo Heller, Mei El...> ;Journal of Hepatology. 2017 Mar 1
• 33 citations
  Pancreatic Squamous Cell Carcinoma: A Population-Based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes.
  Oxana V. Makarova-Rusher, Susanna Varkey Ulahannan, Tim F. Greten, Austin G. Duffy> ;Pancreas. 2016 Nov 1
• 43 citations
  Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination w...
  Austin G. Duffy, Oxana V. Makarova-Rusher, Susanna Varkey Ulahannan, Osama E. Rahma, Suzanne Fioravanti, Melissa Walker, Shahed Abdullah, Mark Raffeld, Victoria L. And...> ;International Journal of Cancer. 2016 Oct 1
• 2 citations
  Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?
  Susanna Varkey Ulahannan, Austin G. Duffy> ;Hepatic Oncology. 2016 Aug 19
• 205 citations
  Population attributable fractions of risk factors for hepatocellular carcinoma in the United States
  Oxana V. Makarova-Rusher, Sean F. Altekruse, Tim S. McNeel, Susanna Varkey Ulahannan, Austin G. Duffy, Barry I. Graubard, Tim F. Greten, Katherine A. McGlynn> ;Cancer. 2016 Jun 1
• 34 citations
  A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib
  Austin G. Duffy, Susanna Varkey Ulahannan, Liang Cao, Osama E. Rahma, Oxana V. Makarova-Rusher, David E. Kleiner, Suzanne Fioravanti, Melissa Walker, Stephanie L. Care...> ;United European Gastroenterology Journal. 2015 Oct 1
• 9 citations
  Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades
  Susanna Varkey Ulahannan, Osama E. Rahma, Austin G. Duffy, Oxana V. Makarova-Rusher, Metin Kurtoglu, David J. Liewehr, Seth M. Steinberg, Tim F. Greten> ;Hepatic Oncology. 2015 Jan 1
• 76 citations
  Earlier presentation and application of curative treatments in hepatocellular carcinoma.
  Susanna Varkey Ulahannan, Austin G. Duffy, Timothy S. McNeel, Jonathan Kish, Lois A. Dickie, Osama E. Rahma, Katherine A. McGlynn, Tim F. Greten, Sean F. Altekruse> ;Hepatology. 2014 Nov 1
• 62 citations
  Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
  Susanna Varkey Ulahannan, Julie R. Brahmer> ;Cancer Investigation. 2011 Apr 6
• Join now to see all

Journal Articles

• Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?  
  Ulahannan SV, Duffy AG, Hepatic Oncology, 8/19/2016
• Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750 - an antisense oligonucleotide against eIF4E - in combinati...  
  Duffy A, Makarova-Rusher OV, Ulahannan SV et al, Internal Journal of Cancer, 1/19/2016
• Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades  
  Ulahannan SV, Rahma OE, Duffy AG, et al, Hepatic Oncology, 1/1/2015
• A phase II study of TRC 105 in patients with hepatocellular carcinoma who have progressed on Sorafenib  
  Duffy A, Ulahannan SV, Cao L et al, United European Gastroenterology Journal, 1/1/2015
• Antiangiogenic Agents in Combination with Chemotherapy in Patients with Non-Small-Cell Lung Cancer  
  Ulahannan SV, Brahmer JR, Cancer Investigation, 1/1/2011
• Join now to see all

Books/Book Chapters

• Cancer Therapeutic Targets 
  Chapter: VEGF 
  Ulahannan SVEditors: Howard L. Kaufman and John L. Marshall.Springer
• Hematology-Oncology Therapy 
  Chapter: Gallbladder Cancer and Cholangiocarcinoma 
  Greten T, Ulahannan SVEditors: Tito Fojo.

Abstracts/Posters

• Tremelimumab: A monoclonal antibody against CTLA-4-In combination with subtotal ablation (trans catheter arterial chemoembolization (TACE), radiofrequency ablation (RF...
  Austin G. Duffy, Oxana V. Makarova-Rusher, Susanna Ulahannan et al, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, 1/1/2016
• Epidemiology and Survival in Patients with Extragastric Signet Ring Carcinoma
  C Kim, SV Ulahannan, J Strauss et al, American association for Cancer Research (AACR), New Orleans, LA, 1/1/2016
• Pretreatment CEA levels predict survival in patients with rectal adenocarcinoma
  OV Makarova-Rusher, J Strauss, SV Ulahannan et al, American association for Cancer Research (AACR), New Orleans, LA, 1/1/2016
• Pancreatic squamous cell carcinoma: Epidemiology, clinicopathologic characteristics, and outcomes
  OV Makarova-Rusher, SV Ulahannan, AG Duffy et al, J Clin Oncol; Gastrointestinal Cancers Symposium, San Francisco, CA, 1/1/2015
• Curative treatments and survival benefits in elderly patients with hepatocellular carcinoma: A SEER population-based analysis
  OV Makarova-Rusher, SV Ulahannan, AG Duffy et al, J Clin Oncol; Gastrointestinal Cancers Symposium, San Francisco, CA, 1/1/2015
• A phase I/II study of TRC 105 in combination with sorafenib in hepatocellular carcinoma (HCC)
  AG Duffy, C Ma, SV Ulahannan et al, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, 1/1/2015
• Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer. Final results
  OV Makarova-Rusher, AG Duffy SV Ulahannan, et al, J Clin Oncol; Gastrointestinal Cancers Symposium, San Francisco, CA, 1/1/2015
• Risk factors for hepatocellular carcinoma (HCC) by race/ethnicity in the United States
  OV Makarova-Rusher, SF Aletekrus, TF McNeel, BI Graubard, AG Duffy, SV Ulahannan et al, AACR annual meeting, 1/1/2015
• Racial/ethnic disparitiesin hepatocellular carcinoma treatment and survival: Are we making progress?
  OV Makarova-Rusher, KA Erokhina, AG Duffy, SV Ulahannan, TF Greten, J Clin Oncol, 1/1/2015
• Disconnect between earlier presentation patterns and application of curative treatments in HCC
  SV Ulahannan, A. Duffy, J. Kish, K. McGlynn, O. Rahma, T. Greten, S. Altekruse, J Clin Oncol; Gastrointestinal Cancers Symposium, San Francisco, CA, 1/1/2014
• Systemic chemotherapy for the treatment of advanced biliary tract carcinoma (BTC)
  SV Ulahannan, OE Rahma, Liewehr J et al, J Clin Oncol, 1/1/2014
• Changing patterns of hepatocellular carcinoma incidence, tumor size and treatment in SEER registries, 2000-2010
  SV Ulahannan, A. Duffy, TS McNeel, KA McGlynn, TF Greten, S Altekruse, 14th Annual CCR Fellows and Young Investigators Colloquium, 1/1/2014
• TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sor...
  A Duffy, C Ma, SV Ulahannan, S Fioravanti, A Venkatesan, I Turkbey, PL Choyke, JB.Trepel, L Cao, K Compton, WD Figg, TF Greten, J Clin Oncol; Gastrointestinal Cancers Symposium, San Francisco, CA, 1/1/2014
• A pilot study of tremelimumab, a monoclonal antibody against CTLA-4, in combination with either TACE or RFA in patients with HCC
  Duffy A, Ulahannan SV, Fioravanti S, J Clin Oncol, 1/1/2014
• Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab - a monoclonal antibody against CTLA-4 in combination with ablative therapy in ...
  AG Duffy, SP Kerkar, DE Kleiner, SV Ulahannan et al, Journal for ImmunoTherapy of Cancer; Annual Meeting of Society for Immunotherapy of Cancer, National Harbor, MD, 1/1/2014
• Trc105 For The Treatment Of Hepatocellular Carcinoma: Preclinical Data And Preliminary Results From Two Clinical Trials Evaluating Monotherapy And Combination With Sor...
  Duffy A, Ma C, Ulahannan SV, Rahma O, Fioravanti S, Venkatesan A, Turkbey B, Choyke P, Trepel J, Figg W, Greten T, International Liver Cancer Association Annual meeting, Washington, DC, 1/1/2013
• A phase II study of TRC105 in patients with hepatocellular carcinoma C (HCC) who have progressed on sorafenib
  A Duffy, OE Rahma, SV Ulahannan et al, J Clin Oncol, 1/1/2013
• Join now to see all